How a Poorly Explored Immune Cell May Impact Cancer Immunity, Immunotherapy – Laboratory Equipment
Laboratory Equipment |
How a Poorly Explored Immune Cell May Impact Cancer Immunity, Immunotherapy
Laboratory Equipment The immune cells trained to fight off the body’s invaders can become defective. It’s what allows cancer to develop. So most cancer immunotherapy research has targeted these so-called effector T cells. But a new study steps back and considers: What if … |
European Biotechnology |
Roche win boosts case for adding chemo to cancer immunotherapy
Reuters LONDON, Nov 20 (Reuters) – Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche’s immune … Roche chemo-immunotherapy combo mets NSCLC Phase III endpointEuropean Biotechnology Roche reshuffles lung cancer immunotherapy market with positive clinical trial resultsSTAT Roche announces trial successes in cancer, haemophiliaNasdaq Xconomy –pharmaphorum –Forbes all 28 news articles » |
San Marcos Corridor News |
FDA Warns About Unapproved, Unproven Stem Cell Therapies, Suggests Confirmation On All Treatments
San Marcos Corridor News Stem cells have been called everything from cure-alls to miracle treatments. But don’t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous procedures—and … Single Cell Analysis Market to Grow Owing to Rising Prevalence of Life Threatening Diseases Till 2024 | Million InsightsPR Newswire (press release) |
Boston Business Journal |
ZIOPHARM’s gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early …
Seeking Alpha ZIOPHARM (NASDAQ:ZIOP) is up 13% premarket on average volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing Ad-RTS-hIL-12 + veledimex in patients with recurrent glioblastoma (rGBM). The data were … Ziopharm says its brain cancer drug helped trial patients live more than a yearBoston Business Journal |